Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 5,054 shares traded hands during trading, a decline of 19% from the previous session's volume of 6,208 shares.The stock last traded at $11.20 and had previously closed at $10.75.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer upped their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th.
Get Our Latest Stock Report on Pharming Group
Pharming Group Trading Down 1.9%
The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business's 50 day simple moving average is $9.70 and its 200 day simple moving average is $9.20. The company has a market capitalization of $755.82 million, a price-to-earnings ratio of -42.73 and a beta of 0.02.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Research analysts anticipate that Pharming Group will post -0.2 EPS for the current year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
